News for Timber Pharmaceuticals, Inc. (BPC2.F)

Today's Daily Dose brings you news about the regulatory set back of Athenex's oral Paclitaxel and CorMedix's Defencath, ASLAN Pharma's Atopic Dermatitis trial results, FDA panel review of FibroGen's Roxadustat, Morphic Therapeutic's Phase 1 single ascending dose clinical trial of MORF-057, which is in development for the treatment of inflammatory bowel disease, and STRATA Skin's CEO transition.

Penny Stocks For The Early-March Watch List As March gets off to a great start, investors continue to look for penny stocks with the best chance of profitabili...

Today's Daily Dose brings you news about temporary suspension of bluebird bio's gene therapy trials in sickle cell disease, Sesen Bio's regulatory catalyst for this year, partial hold on Cortexyme's open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimer's disease, and expanded FDA approval of Novartis' Entresto.

(RTTNews) - Today's Daily Dose brings you news about temporary suspension of bluebird bio's gene therapy trials in sickle cell disease, Sesen Bio'...

These Penny Stocks May Be To Active To Ignore We’re at the start of a new week, and you better believe research is already getting done on which penny stocks...

Are These The Best Penny Stocks To Buy Today? In this article, we’ll go over some of the basics of penny stocks. What are they, how do you find them, and sho...

Gainers Live Ventures Incorporated (NASDAQ:LIVE) shares jumped 90.4% to close at $23.90 on Wednesday after the company swung to a profit in the ...

Gainers Summit Midstream Partners, LP (NYSE:SMLP) shares rose 58.3% to $21.67 in pre-market trading after the company reported achievement of ke...

Timber Expects to Submit Investigational New Drug (IND) Application to the FDA in 2022 WOODCLIFF LAKE, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- via...